tetano
Editor, Senior Moderator
Lupus
. 2022 Apr 5;9612033221093502.
doi: 10.1177/09612033221093502. Online ahead of print.
COVID-19 in patients with systemic lupus erythematosus: A systematic review
Xue-Lei Fu[SUP] 1 [/SUP], Yan Qian[SUP] 2 [/SUP], Xiao-Hong Jin[SUP] 2 [/SUP], Hai-Rong Yu[SUP] 2 [/SUP], Lin Du[SUP] 1 [/SUP], Hua Wu[SUP] 1 [/SUP], Hong-Lin Chen[SUP] 3 [/SUP], Ya-Qin Shi[SUP] 1 [/SUP]
Affiliations
Abstract
The objectives of the study were to review the articles to identify (a) the epidemiology of systemic lupus erythematosus (SLE) and coronavirus disease 2019 (COVID-19); (b) the clinical characteristics of SLE patients with COVID-19; (c) the treatment of COVID-19 in SLE patients; and (d) the impact of COVID-19 pandemic on SLE patients. PubMed was systematically reviewed for literature published from December 2019 to June 2021. Our search was limited to human studies, with language restriction of English. Studies were included if they reported COVID-19 in SLE patients. Our systematic review included 52 studies. The prevalence of COVID-19 infection ranged from 0.0% to 18.1% in SLE patients, and the hospitalisation rates ranged from 0.24% to 10.6%. COVID-19 infection is likely to mimic SLE flare. Hydroxychloroquine (HCQ) was ineffective in prevention of COVID-19, and SLE patients with COVID-19 faced difficulty in healthcare access, had financial constraints and suffered from psychological distress during the pandemic. The pandemic had a significant effect on mental and physical health. Adequate healthcare access, along with containment policies, social distancing measures and psychological nursing was required.
Keywords: COVID-19; SARS-CoV-2; SLE; Systematic Review.
. 2022 Apr 5;9612033221093502.
doi: 10.1177/09612033221093502. Online ahead of print.
COVID-19 in patients with systemic lupus erythematosus: A systematic review
Xue-Lei Fu[SUP] 1 [/SUP], Yan Qian[SUP] 2 [/SUP], Xiao-Hong Jin[SUP] 2 [/SUP], Hai-Rong Yu[SUP] 2 [/SUP], Lin Du[SUP] 1 [/SUP], Hua Wu[SUP] 1 [/SUP], Hong-Lin Chen[SUP] 3 [/SUP], Ya-Qin Shi[SUP] 1 [/SUP]
Affiliations
- PMID: 35382637
- DOI: 10.1177/09612033221093502
Abstract
The objectives of the study were to review the articles to identify (a) the epidemiology of systemic lupus erythematosus (SLE) and coronavirus disease 2019 (COVID-19); (b) the clinical characteristics of SLE patients with COVID-19; (c) the treatment of COVID-19 in SLE patients; and (d) the impact of COVID-19 pandemic on SLE patients. PubMed was systematically reviewed for literature published from December 2019 to June 2021. Our search was limited to human studies, with language restriction of English. Studies were included if they reported COVID-19 in SLE patients. Our systematic review included 52 studies. The prevalence of COVID-19 infection ranged from 0.0% to 18.1% in SLE patients, and the hospitalisation rates ranged from 0.24% to 10.6%. COVID-19 infection is likely to mimic SLE flare. Hydroxychloroquine (HCQ) was ineffective in prevention of COVID-19, and SLE patients with COVID-19 faced difficulty in healthcare access, had financial constraints and suffered from psychological distress during the pandemic. The pandemic had a significant effect on mental and physical health. Adequate healthcare access, along with containment policies, social distancing measures and psychological nursing was required.
Keywords: COVID-19; SARS-CoV-2; SLE; Systematic Review.